Autolus Therapeutics (AUTL) Other Non-Current Liabilities (2017 - 2025)
Autolus Therapeutics posted quarterly Other Non-Current Liabilities of $477000.0 for Q4 2025, up 11.97% year-on-year from $426000.0 in Q4 2024, and up 1.06% on a QoQ basis from $472000.0 in Q3 2025.
Autolus Therapeutics (AUTL) has 7 years of Other Non-Current Liabilities data on file, last reported at $477000.0 in Q4 2025.
- For the quarter ending Q4 2025, Other Non-Current Liabilities rose 11.97% year-over-year to $477000.0; the trailing twelve-month figure through Dec 2025 stood at $477000.0 (up 11.97% YoY), and the FY2025 full-year result was $477000.0, up 11.97% from the prior year.
- Other Non-Current Liabilities for Q4 2025 stood at $477000.0, up from $472000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $477000.0 in Q2 2025 and bottomed at $105000.0 in Q3 2022.
- The 5-year median for Other Non-Current Liabilities is $357000.0 (2023), against an average of $296647.1.
- The widest annual swing landed in 2022, when Other Non-Current Liabilities fell 9.38%; it then surged 258.77% in 2024.
- A 5-year view of Other Non-Current Liabilities shows it stood at $128000.0 in 2021, then dropped by 9.38% to $116000.0 in 2022, then soared by 207.76% to $357000.0 in 2023, then grew by 19.33% to $426000.0 in 2024, then advanced by 11.97% to $477000.0 in 2025.
- The last three Other Non-Current Liabilities figures came in at $477000.0 (Q4 2025), $472000.0 (Q3 2025), and $477000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Autolus Therapeutics | - | - | -1.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 477,000.00 |
| Sep 30, 2025 | 472,000.00 |
| Jun 30, 2025 | 477,000.00 |
| Mar 31, 2025 | 444,000.00 |
| Dec 31, 2024 | 426,000.00 |
| Sep 30, 2024 | 447,000.00 |
| Jun 30, 2024 | 415,000.00 |
| Mar 31, 2024 | 409,000.00 |
| Dec 31, 2023 | 357,000.00 |
| Sep 30, 2023 | 295,000.00 |
| Jun 30, 2023 | 122,000.00 |
| Mar 31, 2023 | 114,000.00 |
| Dec 31, 2022 | 116,000.00 |
| Sep 30, 2022 | 105,000.00 |
| Jun 30, 2022 | 115,000.00 |
| Mar 31, 2022 | 124,000.00 |
| Dec 31, 2021 | 128,000.00 |
| Dec 31, 2018 | 207,000.00 |
| Sep 30, 2018 | 221,000.00 |
| Sep 30, 2017 | 265,000.00 |